Clinical Trial Update: Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS) [Phase 3]

View source ↗

Summary

Phase 3 trial update for rifaximin 3 times daily in non-constipation irritable bowel syndrome (IBS) completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Non-Constipation Irritable Bowel Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2014-07-28